A5074460989- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- Immune cells in cancer
- Cancer Genomics and Diagnostics
- Phagocytosis and Immune Regulation
- Immunotherapy and Immune Responses
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Neuroendocrine Tumor Research Advances
- Neuroblastoma Research and Treatments
- Hepatocellular Carcinoma Treatment and Prognosis
- Chemokine receptors and signaling
- Immune Cell Function and Interaction
- Pancreatitis Pathology and Treatment
- Cancer Cells and Metastasis
- Radiopharmaceutical Chemistry and Applications
- Gastric Cancer Management and Outcomes
- Gallbladder and Bile Duct Disorders
- Cancer Research and Treatments
- Epigenetics and DNA Methylation
- Colorectal Cancer Treatments and Studies
- CAR-T cell therapy research
- T-cell and B-cell Immunology
- Single-cell and spatial transcriptomics
- Cancer, Stress, Anesthesia, and Immune Response
- Inflammatory Biomarkers in Disease Prognosis
University of Rochester Medical Center
2016-2025
University of Rochester
2016-2025
Our Lady of Lourdes Hospital
2023-2024
Washington University in St. Louis
2010-2021
Mater Misericordiae University Hospital
2021
University College Dublin
2021
University of North Carolina at Chapel Hill
2021
Vaccinex (United States)
2021
Bipar
2020
Barnes-Jewish Hospital
2005-2016
Abstract Regulatory T cells (Treg) that prevent autoimmune diseases by suppression of self-reactive may also suppress the immune response against cancer. In mice, depletion Treg Ab therapy leads to more efficient tumor rejection. Treg-mediated antitumor responses partly explain poor clinical vaccine-based immunotherapy for human this study, we measured prevalence coexpress CD4 and CD25 in PBLs, tumor-infiltrating lymphocytes, regional lymph node lymphocytes from 65 patients with either...
Abstract Cancer immunotherapy generally offers limited clinical benefit without coordinated strategies to mitigate the immunosuppressive nature of tumor microenvironment. Critical drivers immune escape in microenvironment include tumor-associated macrophages and myeloid-derived suppressor cells, which not only mediate suppression, but also promote metastatic dissemination impart resistance cytotoxic therapies. Thus, ablate effects these myeloid cell populations may offer great therapeutic...
Tumor-infiltrating immune cells can promote chemoresistance and metastatic spread in aggressive tumors. Consequently, the type quality of responses present neoplastic stroma are highly predictive patient outcome several cancer types. In addition to host responses, intrinsic tumor cell activities that mimic stem properties have been linked chemoresistance, dissemination, induction suppression. Cancer far from a static population; rather, their presence seems be controlled by dynamic processes...
To report the first 5-year overall survival results in patients with colorectal carcinoma metastatic to liver who have undergone hepatic resection after staging [18F] fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET).The for cancer metastases without preoperative FDG-PET has been established 19 studies (6070 patients). The median rate these is 30% and not improved over time. detects unsuspected tumor 25% of considered resectable metastasis by conventional staging.From March...
To determine the role of CCL2/CCR2 axis and inflammatory monocytes (CCR2(+)/CD14(+)) as immunotherapeutic targets in treatment pancreatic cancer.Survival analysis was conducted to if prevalence preoperative blood correlates with survival patients cancer following tumor resection. Inflammatory monocyte bone marrow controls compared. The immunosuppressive properties macrophages tumors, respectively, were assessed. CCL2 expression by human tumors compared normal pancreas. A novel CCR2 inhibitor...
The identification of antigenic peptides presented on the tumor cell surface by HLA class I molecules and recognized tumor-specific cytotoxic T lymphocytes may lead to a peptide vaccine capable inducing protective cellular immunity. We demonstrate that both HLA-A2-restricted breast ovarian recognize shared peptides. At least one these is derived from oncogene product HER2/neu, which overexpressed in 30-40% all cancers. cells sensitized against this nine-amino acid sequence significant...
Pancreatic adenocarcinoma has the worst mortality of any solid cancer. In this study, to evaluate clinical implications genomic alterations in tumour type, we perform whole-exome analyses 24 tumours, targeted 77 and use non-invasive approaches examine tumour-specific mutations circulation these patients. These reveal somatic chromatin-regulating genes MLL, MLL2, MLL3 ARID1A 20% patients that are associated with improved survival. We observe potential therapeutic utility over a third cases....
To update the analysis of technical and biologic factors related to hepatic resection for colorectal metastasis in a large single-institution series identify important prognostic indicators patterns failure.Surgical therapy carcinoma metastatic liver is only potentially curable treatment. Careful patient selection those with resectable liver-only disease crucial success surgical therapy.Two hundred forty-four consecutive patients undergoing curative were analyzed retrospectively. Variables...
Tumors evade immune destruction by actively inducing tolerance through the recruitment of CD4(+)CD25(+)Foxp3(+) regulatory T cells (Treg). We have previously described increased prevalence these in pancreatic adenocarcinoma, but it remains unclear what mechanisms are involved recruiting Tregs into tumor microenvironment. Here, we postulated that chemokines might direct Treg homing to tumor. show, both human adenocarcinoma and a murine model (Pan02), produce levels ligands for CCR5 chemokine...
Objective Chemokine pathways are co-opted by pancreatic adenocarcinoma (PDAC) to facilitate myeloid cell recruitment from the bone marrow establish an immunosuppressive tumour microenvironment (TME). Targeting tumour-associated CXCR2 + neutrophils (TAN) or CCR2 macrophages (TAM) alone improves antitumour immunity in preclinical models. However, a compensatory influx of alternative subset may result persistent TME and promote therapeutic resistance. Here, we show combined blockade reduces...
To explore the prognostic importance and preoperative predictors of lymph node metastasis in an effort to guide surgical decision making patients with pancreatic neuroendocrine tumors (PNETs).PNETs are uncommon, natural history disease is not well described. As a result, there remains controversy regarding optimal management regional nodes during resection primary tumor.A retrospective review prospectively maintained database who underwent surgery for locoregional PNET between 1994 2012 was...
Although patients with resected pancreatic adenocarcinoma are at high risk for disease recurrence, few biomarkers available to inform patient outcomes.To evaluate the alterations of 4 main driver genes in and outcomes after cancer resection.This study analyzed protein expression DNA KRAS, CDKN2A, SMAD4, TP53 by immunohistochemistry next-generation sequencing formalin-fixed, paraffin-embedded tumors 356 who were treated Dana-Farber/Brigham Women's Cancer Center (October 26, 2002, May 21,...
Pancreatic cancer (PC) mobilizes myeloid cells from the bone marrow to tumor where they promote growth and proliferation. Cancer stem (CSCs) are a population of that responsible for initiation. Aldehyde dehydrogenase-1 activity in PC identifies CSCs, its has been correlated with poor overall prognosis human PC. Myeloid have shown impact stemness, but immunosuppressive tumor-infiltrating granulocytic monocytic myeloid-derived suppressor (Mo-MDSC) on ALDH1(Bright) CSCs epithelial mesenchymal...
Tumors employ multiple mechanisms to evade immune surveillance. One mechanism is tumor-induced myelopoiesis, whereby the expansion of immunosuppressive myeloid cells can impair tumor immunity. As and conventional dendritic (cDCs) are derived from same progenitors, we postulated that myelopoiesis might impact cDC development. The subset, cDC1, which includes human CD141+ DCs mouse CD103+ DCs, supports anti-tumor immunity by stimulating CD8+ T-cell responses. Here, understand how cDC1...
Abstract Purpose: Molecular subtyping for pancreatic cancer has made substantial progress in recent years, facilitating the optimization of existing therapeutic approaches to improve clinical outcomes cancer. With advances treatment combinations and choices, it is becoming increasingly important determine ways place patients on best therapies upfront. Although various molecular systems have been proposed, consensus regarding proposed subtypes, as well their relative utility, remains largely...
Background In pancreatic ductal adenocarcinoma (PDAC), the chemokine (C-C motif) ligand 2 (CCL2)/chemokine receptor (CCR2) axis plays a key role in immunosuppressive properties of tumor microenvironment, patient prognosis, and chemoresistance. This phase Ib study assessed effects orally administered CCR2 inhibitor PF-04136309 combination with nab-paclitaxel gemcitabine patients previously untreated metastatic PDAC. Methods Patients received twice daily (BID) continuously plus (125 mg/m2)...